Vaishali Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
VAISHALI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vaishali Pharma Limited reported audited FY25 results with revenue from operations of ₹9,902.56 lakhs, up about 15% from ₹8,627.97 lakhs in FY24. Full-year net profit rose to ₹81.73 lakhs from ₹71.89 lakhs, but the March quarter alone posted a sharp loss of ₹429.26 lakhs, weighing on profitability. The auditor issued a qualified opinion, flagging that they could not obtain sufficient evidence regarding recovery of ₹1,334.58 lakhs in trade receivables older than 3 years, ₹2,558.28 lakhs in deposits and advances, and ₹2,138.81 lakhs paid as advances to suppliers. Total assets expanded sharply to ₹10,984.49 lakhs, supported by ₹2,125.64 lakhs raised through share warrants and an improvement in operating cash flow to ₹1,803.83 lakhs. Annual EPS slipped to ₹0.31 from ₹0.67, partly due to the enlarged equity base after the warrant issuance.
The qualified audit opinion and the large pile of unverified old receivables and advances raise concerns about asset quality, while the steep Q4 loss signals margin pressure. Shareholders should watch how the company recovers these stuck receivables and whether it can translate revenue growth into consistent profits.